Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel
出版年份 2020 全文链接
标题
Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel
作者
关键词
-
出版物
Nature Biomedical Engineering
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-08-11
DOI
10.1038/s41551-020-0597-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
- (2020) Feihu Wang et al. Science Advances
- Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy
- (2019) Daniel Shae et al. Nature Nanotechnology
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy
- (2018) David G. Leach et al. BIOMATERIALS
- Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy
- (2018) David R. Wilson et al. Nanomedicine-Nanotechnology Biology and Medicine
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
- (2018) Chun Gwon Park et al. Science Translational Medicine
- In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
- (2018) Chao Wang et al. Science Translational Medicine
- RecombinantListeriapromotes tumor rejection by CD8+T cell-dependent remodeling of the tumor microenvironment
- (2018) Weiwen Deng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response
- (2018) Assaf Marcus et al. IMMUNITY
- In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
- (2018) Qian Chen et al. Nature Nanotechnology
- Rationale for stimulator of interferon genes–targeted cancer immunotherapy
- (2017) Thaiz Rivera Vargas et al. EUROPEAN JOURNAL OF CANCER
- Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model
- (2017) Shekhar K. Gadkaree et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation
- (2016) Ken Takashima et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
- (2016) Haidong Tang et al. CANCER CELL
- Chemotherapy and immunotherapy: mapping the road ahead
- (2016) Alistair M Cook et al. CURRENT OPINION IN IMMUNOLOGY
- Make better, safer biomaterials
- (2016) Nicholas A. Peppas et al. NATURE
- Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
- (2016) D. Mathios et al. Science Translational Medicine
- Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
- (2016) E. Moore et al. Cancer Immunology Research
- Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment
- (2015) Giuseppe Lombardi et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
- (2015) Olivier Demaria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T cell exclusion, immune privilege, and the tumor microenvironment
- (2015) J. A. Joyce et al. SCIENCE
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Linker-determined drug release mechanism of free camptothecin from self-assembling drug amphiphiles
- (2014) Andrew G. Cheetham et al. CHEMICAL COMMUNICATIONS
- Intrinsic Self-DNA Triggers Inflammatory Disease Dependent on STING
- (2014) Jeonghyun Ahn et al. JOURNAL OF IMMUNOLOGY
- STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
- (2014) D. Chandra et al. Cancer Immunology Research
- Murine leukemia virus envelope gp70 is a shared biomarker for the high-sensitivity quantification of murine tumor burden
- (2014) Francesca Scrimieri et al. OncoImmunology
- Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation
- (2014) Lotte Spel et al. OncoImmunology
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy
- (2013) Christel Devaud et al. MOLECULAR THERAPY
- cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING
- (2013) Andrea Ablasser et al. NATURE
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
- (2012) J. Wu et al. SCIENCE
- Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
- (2012) L. Sun et al. SCIENCE
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
- (2009) Kazuki N. Sugahara et al. CANCER CELL
- STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
- (2009) Hiroki Ishikawa et al. NATURE
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
- (2008) Hiroki Ishikawa et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation